Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hancock Jaffe Changes Name To enVVeno, Drops Cardiac Device To Focus On Venous Disease

Executive Summary

The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.

You may also be interested in...



Hancock Jaffe Sells $41.4M In Stock To Fund Venous Therapies

The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.

Boston Scientific Co-Founder Pete Nicholas Dies

Nicholas co-founded Boston Scientific in 1979 with John Abele. He served as the company’s CEO from 1979 until 1999 and as chairman until 2016.

Digital Health Roundup: AI Trends In Medtech; Exec Chats; FDA’s Digital Health Guru Steps Down

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights AI trends in medtech, Exec Chats with iRhythm and medical robotics authority Moshe Shoham, and key FDA updates.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel